<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7923310</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">33648569</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">7923310</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">415</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1186/s13229-021-00415-z</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Characterization of sample merged across ABIDE I and II Cluster masks are overlaid on inflated brain maps generated by BrainNet Viewer</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Characterization of sample merged across ABIDE I and II Cluster masks are overlaid on inflated brain maps generated by BrainNet Viewer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">ABIDE I + II</th><th align="left">Sites<sup>a</sup></th><th align="left">ASD M (<italic>N</italic> = 362)</th><th align="left">ASD F (<italic>N</italic> = 82)</th><th align="left">NT M (<italic>N</italic> = 409)</th><th align="left">NT F (<italic>N</italic> = 166)</th><th align="left" rowspan="2">Statistics</th><th align="left" rowspan="2">Post-hoc</th></tr><tr><th align="left"><italic>N</italic></th><th align="left">Mean (SD) [Range]</th><th align="left">Mean (SD) [Range]</th><th align="left">Mean (SD) [Range]</th><th align="left">Mean (SD) [Range]</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">13</td><td align="left">11.8 (2.6) [7–17.9]</td><td align="left">11.7 (2.7) [7–18]</td><td align="left">11.8 (2.6) [7.1–18.2]</td><td align="left">11.4 (2.3) [7.8–17.4]</td><td align="left"><italic>F</italic><sub>(3)</sub> = 1.18 <italic>p</italic> = 0.32</td><td align="left"/></tr><tr><td align="left">Full-Scale IQ<sup>b</sup></td><td align="left">13</td><td align="left">106 (16.6) [72–148]</td><td align="left">104 (16.3) [73–147]</td><td align="left">112 (12.7) [73–148]</td><td align="left">114 (12.7) [80–144]</td><td align="left"><italic>F</italic><sub>(3)</sub> = 19.24 <italic>p</italic> &lt; 0.001</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left">Verbal IQ<sup>c</sup></td><td align="left">12</td><td align="left">107 (17.9) [57–180]</td><td align="left">105 (17.3) [62–145]</td><td align="left">114 (13.5) [73–147]</td><td align="left">114 (14.4) [83–146]</td><td align="left"><italic>F</italic><sub>(3)</sub> = 16.78 <italic>p</italic> &lt; 0.001</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left">Performance IQ<sup>d</sup></td><td align="left">12</td><td align="left">106 (17.0) [59–157]</td><td align="left">104 (17.1) [67–148]</td><td align="left">109 (14.2) [62–147]</td><td align="left">109 (13.2) [79–145]</td><td align="left"><italic>F</italic><sub>(3)</sub> = 3.1 <italic>p</italic> = 0.03</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left">Mean FD</td><td align="left">13</td><td align="left">0.11 (0.07) [0.02–0.39]</td><td align="left">0.13 (0.09) [0.02–0.39]</td><td align="left">0.09 (0.06) [0.02–0.39]</td><td align="left">0.09 (0.06) [0.02–0.38]</td><td align="left"><italic>H</italic><sub>(3)</sub> = 29.6 <italic>p</italic> &lt; 0.001</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left" colspan="8"><italic>ADI-R</italic></td></tr><tr><td align="left">Social<sup>e</sup></td><td align="left">11</td><td align="left">19.7 (5.2) [4–30]</td><td align="left">19.6 (5.5) [7–30]</td><td align="left">–</td><td align="left">–</td><td align="left"><italic>t</italic><sub>(93)</sub> = 0.14 <italic>p</italic> = 0.89</td><td align="left"/></tr><tr><td align="left">Communication<sup>f</sup></td><td align="left">11</td><td align="left">15.6 (4.5) [2–25]</td><td align="left">15.2 (5.0) [4–24]</td><td align="left">–</td><td align="left">–</td><td align="left"><italic>t</italic><sub>(92)</sub> = 0.61 <italic>p</italic> = 0.54</td><td align="left"/></tr><tr><td align="left">RRB<sup>f</sup></td><td align="left">11</td><td align="left">6.0 (2.4) [0–13]</td><td align="left">5.8 (2.5) [0–12]</td><td align="left">–</td><td align="left">–</td><td align="left"><italic>t</italic><sub>(96)</sub> = 0.51 <italic>p</italic> = 0.61</td><td align="left"/></tr><tr><td align="left" colspan="8"><italic>ADOS-2</italic></td></tr><tr><td align="left">Social-Affect<sup>g</sup></td><td align="left">11</td><td align="left">9.1 (3.7) [1–20]</td><td align="left">8.7 (3.2) [4–18]</td><td align="left">–</td><td align="left">–</td><td align="left"><italic>t</italic><sub>(87)</sub> = 0.97 <italic>p</italic> = 0.33</td><td align="left"/></tr><tr><td align="left">RRB<sup>h</sup></td><td align="left">11</td><td align="left">3.2 (1.8) [0–8]</td><td align="left">2.8 (1.5) [0–5]</td><td align="left">–</td><td align="left">–</td><td align="left"><italic>t</italic><sub>(93)</sub> = 1.79 <italic>p</italic> = 0.08</td><td align="left"/></tr><tr><td align="left">CSS total<sup>i</sup></td><td align="left">11</td><td align="left">6.9 (2.1) [1–10]</td><td align="left">6.8 (1.8) [2–10]</td><td align="left">–</td><td align="left">–</td><td align="left"><italic>t</italic><sub>(93)</sub> = 0.11 <italic>p</italic> = 0.32</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left"><italic>N</italic></td><td align="left"><italic>N</italic></td><td align="left"/><td align="left"/><td align="left">Statistics</td><td align="left">Post-hoc</td></tr><tr><td align="left">Comorbidity</td><td align="left">5</td><td align="left">99<sup>j</sup></td><td align="left">25<sup>k</sup></td><td align="left">–</td><td align="left">–</td><td align="left"><italic>χ</italic><sup>2</sup><sub>(1)</sub> = 0.2 <italic>p</italic> = 0.66</td><td align="left"/></tr><tr><td align="left">Psychoactive medication</td><td align="left">10</td><td align="left">112</td><td align="left">26</td><td align="left">–</td><td align="left">–</td><td align="left"><italic>χ</italic><sup>2</sup><sub>(1)</sub> &lt; 0.01 <italic>p</italic> = 0.99</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>ABIDE</italic> Autism Brain Imaging data exchange, <italic>ADI-R</italic> Autism Diagnostic Interview-Revised, <italic>ADOS-2</italic> Autism Diagnostic Observation Schedule-2, <italic>ASD</italic> Autism Spectrum Disorder, <italic>CSS</italic> Calibrated Severity Score, <italic>F</italic> females, <italic>IQ</italic> intellectual quotient, <italic>M</italic> males, <italic>Mean FD</italic> mean framewise displacement [<xref ref-type="bibr" rid="CR54">54</xref>]; <italic>NT</italic> neurotypical, <italic>RRB</italic> restricted repetitive behaviors</p><p><sup>a</sup>ABIDE I data collections: KKI, Leuven2, NYU, OHSU, Pitt, SDSU, Stanford, UCLA1, UM1, and Yale. ABIDE II data collections: ABIDEII-GU1, ABIDEII-KKI1, ABIDEII-KKI2, ABIDEII-NYU1, ABIDEII-OHSU1, ABIDEII-SDSU1, ABIDEII-UCD1 and ABIDEII-UCLA1. KKI and ABIDEII-KKI1, NYU and ABIDEII-NYU1, SDSU and ABIDEII-SDSU1, OHSU and ABIDEII-OHSU1 and UCLA1 and ABIDEII-UCLA1 were merged into one site across ABIDE I and ABIDE II collections</p><p><sup>b</sup>FIQ was available for 362 males with ASD (2 missing from UM1, ABIDEII-SDSU1), 81 females with ASD (1 missing from ABIDEII-GU1), 407 neurotypical males (NT M) [3 missing from ABIDEII-GU1 (<italic>N</italic> = 1), UM1 (<italic>N</italic> = 2)] and all 166 NT females (NT F)</p><p><sup>c</sup>VIQ was available for 315 males with ASD (47 missing; KKI (<italic>N</italic> = 14), ABIDEII-OHSU1 (<italic>N</italic> = 22), OHSU (<italic>N</italic> = 9), ABIDEII-SDSU1 (<italic>N</italic> = 1); ABIDEII-UCLA1 (<italic>N</italic> = 1), 70 females with ASD [12 missing, ABIDEII-GU1 (<italic>N</italic> = 1), KKI (<italic>N</italic> = 4), ABIDEII-OHSU1 (<italic>N</italic> = 7)], 351 NT M [59 missing; ABIDEII-GU1 (<italic>N</italic> = 1), KKI (<italic>N</italic> = 23), OHSU (<italic>N</italic> = 15), ABIDEII-OHSU1 (<italic>N</italic> = 20)], and 139 NT F [27 missing; KKI (<italic>N</italic> = 8), ABIDEII-OHSU1 (<italic>N</italic> = 19)]</p><p><sup>d</sup>PIQ was available for 306 males with ASD [56 missing; ABIDEII-GU1 (<italic>N</italic> = 9), KKI (<italic>N</italic> = 14), OHSU (<italic>N</italic> = 9), ABIDEII-OHSU1 (<italic>N</italic> = 22), ABIDEII-UCLA1 (<italic>N</italic> = 1), UM1, (<italic>N</italic> = 1)], 67 females with ASD [15 missing; ABIDEII-GU1 (<italic>N</italic> = 4), KKI (<italic>N</italic> = 4), ABIDEII-OHSU1 (<italic>N</italic> = 7)], 349 NT M [61 missing; ABIDEII-GU1 (<italic>N</italic> = 1), KKI (<italic>N</italic> = 23), OHSU (<italic>N</italic> = 15), ABIDEII-OHSU1 (<italic>N</italic> = 20), UM1, (<italic>N</italic> = 2)], 139 NT F [27 missing; KKI (<italic>N</italic> = 8), ABIDEII-OHSU1 (<italic>N</italic> = 19)]</p><p><sup>e</sup>ADI-R Social scores were available for 317 males with ASD [45 missing; ABIDEII-GU1 (<italic>N</italic> = 1), Leuven2 (<italic>N</italic> = 10), NYU (<italic>N</italic> = 3), ABIDEII-NYU1 (<italic>N</italic> = 1), SDSU (<italic>N</italic> = 2), ABIDEII-UCD1 (<italic>N</italic> = 11), ABIDEII-UCLA1 (<italic>N</italic> = 14), UM1, (<italic>N</italic> = 2), Yale (<italic>N</italic> = 3)] and 68 females with ASD [14 missing; ABIDEII-GU1 (<italic>N</italic> = 1), ABIDEII-KKI1 (<italic>N</italic> = 2), Leuven2 (<italic>N</italic> = 3), NYU (<italic>N</italic> = 1), Pitt (<italic>N</italic> = 1), ABIDEII-UCD1 (<italic>N</italic> = 3), ABIDEII-UCLA1 (<italic>N</italic> = 1), Yale (<italic>N</italic> = 2)]</p><p><sup>f</sup>ADI-R Communication and RRB scores were available for 318 males with ASD [45 missing; ABIDEII-GU1 (<italic>N</italic> = 1), Leuven2 (<italic>N</italic> = 10), NYU (<italic>N</italic> = 2), ABIDEII-NYU1 (<italic>N</italic> = 1), SDSU (<italic>N</italic> = 2), ABIDEII-UCD1 (<italic>N</italic> = 11), ABIDEII-UCLA1 (<italic>N</italic> = 14), UM1, (<italic>N</italic> = 2), Yale (<italic>N</italic> = 3)] and 68 females with ASD [14 missing; ABIDEII-GU1 (<italic>N</italic> = 1), ABIDEII-KKI1 (<italic>N</italic> = 2), Leuven2 (<italic>N</italic> = 3), NYU (<italic>N</italic> = 1), Pitt (<italic>N</italic> = 1), ABIDEII-UCD1 (<italic>N</italic> = 3), ABIDEII-UCLA1 (<italic>N</italic> = 1), Yale (<italic>N</italic> = 2)]</p><p><sup>g</sup>ADOS-Gotham Social-Affect was available for 261 males with ASD [101 missing; ABIDEII-GU1 (<italic>N</italic> = 27), ABIDEII-KKI1 (<italic>N</italic> = 13), Leuven2 (<italic>N</italic> = 10), NYU (<italic>N</italic> = 7), OHSU (<italic>N</italic> = 11), Pitt (<italic>N</italic> = 8), SDSU (<italic>N</italic> = 8), Stanford (<italic>N</italic> = 6), ABIDEII-UCLA1 (<italic>N</italic> = 5), UM1 (<italic>N</italic> = 6), Yale (<italic>N</italic> = 1)] and 55 females with ASD [27 missing; ABIDEII-GU1 (<italic>N</italic> = 6), ABIDEII-KKI1 (<italic>N</italic> = 7), Leuven2 (<italic>N</italic> = 3), ABIDEII-OHSU1 (<italic>N</italic> = 1), Pitt (<italic>N</italic> = 4), Stanford (<italic>N</italic> = 1), ABIDEII-UCD1 (<italic>N</italic> = 1), UCLA1 (<italic>N</italic> = 1), UM1 (<italic>N</italic> = 3)]</p><p><sup>h</sup>ADOS-Gotham RRB was available for 264 males with ASD [98 missing; ABIDEII-GU1 (<italic>N</italic> = 27), ABIDEII-KKI1 (<italic>N</italic> = 13), Leuven2 (<italic>N</italic> = 10), NYU (<italic>N</italic> = 7), OHSU (<italic>N</italic> = 11), Pitt (<italic>N</italic> = 8), SDSU (<italic>N</italic> = 8), Stanford (<italic>N</italic> = 3), ABIDEII-UCLA1 (<italic>N</italic> = 5), UM1 (<italic>N</italic> = 6), Yale (<italic>N</italic> = 1)] and 56 females with ASD [26 missing; ABIDEII-GU1 (<italic>N</italic> = 6), ABIDEII-KKI1 (<italic>N</italic> = 7), Leuven2 (<italic>N</italic> = 3), ABIDEII-OHSU1 (<italic>N</italic> = 1), Pitt (<italic>N</italic> = 4), ABIDEII-UCD1 (<italic>N</italic> = 1), UCLA1 (<italic>N</italic> = 1), UM1 (<italic>N</italic> = 3)]</p><p><sup>i</sup>ADOS-Gotham calibrated severity scores [<xref ref-type="bibr" rid="CR65">65</xref>] were available for 347 males with ASD (15 missing) and 77 females with ASD (5 missing)</p><p><sup>j</sup>Attention Deficit Hyperactivity Disorder (ADHD; <italic>N</italic> = 63); anxiety disorder (<italic>N</italic> = 22); Oppositional Defiant Disorder (ODD; <italic>N</italic> = 17); mood disorder (<italic>N</italic> = 11); Tourettes/Tics (<italic>N</italic> = 6); Obsessive–Compulsive Disorder (OCD; <italic>N</italic> = 6); enuresis (<italic>N</italic> = 8); encopresis (<italic>N</italic> = 4); developmental articulation disorder (<italic>N</italic> = 1); developmental dyslexia (<italic>N</italic> = 1); sensory integration disorder (<italic>N</italic> = 1)</p><p><sup>k</sup>ADHD (<italic>N</italic> = 17); anxiety disorder (<italic>N</italic> = 7); ODD (<italic>N</italic> = 10); mood disorder (<italic>N</italic> = 2); OCD (<italic>N</italic> = 2); enuresis (<italic>N</italic> = 2); encopresis (<italic>N</italic> = 1). The three group means were compared with ANOVA tests (or Kruskal–Wallis test in the case of non-parametric mean FD) followed by post-hoc pairwise <italic>t</italic> test comparisons (or Mann–Whitney <italic>U</italic> tests in the case of non-parametric mean FD) when statistically significant (significance cut-off set at <italic>p</italic> &lt; 0.05)</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Characterization of sample merged across ABIDE I and II Cluster masks are overlaid on inflated brain maps generated by BrainNet Viewer</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">ABIDE I + II</th><th align="left">Sitesa</th><th align="left">ASD M (N = 362)</th><th align="left">ASD F (N = 82)</th><th align="left">NT M (N = 409)</th><th align="left">NT F (N = 166)</th><th align="left" rowspan="2">Statistics</th><th align="left" rowspan="2">Post-hoc</th></tr><tr><th align="left">N</th><th align="left">Mean (SD) [Range]</th><th align="left">Mean (SD) [Range]</th><th align="left">Mean (SD) [Range]</th><th align="left">Mean (SD) [Range]</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">13</td><td align="left">11.8 (2.6) [7–17.9]</td><td align="left">11.7 (2.7) [7–18]</td><td align="left">11.8 (2.6) [7.1–18.2]</td><td align="left">11.4 (2.3) [7.8–17.4]</td><td align="left">F(3) = 1.18 p = 0.32</td><td align="left"/></tr><tr><td align="left">Full-Scale IQb</td><td align="left">13</td><td align="left">106 (16.6) [72–148]</td><td align="left">104 (16.3) [73–147]</td><td align="left">112 (12.7) [73–148]</td><td align="left">114 (12.7) [80–144]</td><td align="left">F(3) = 19.24 p &lt; 0.001</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left">Verbal IQc</td><td align="left">12</td><td align="left">107 (17.9) [57–180]</td><td align="left">105 (17.3) [62–145]</td><td align="left">114 (13.5) [73–147]</td><td align="left">114 (14.4) [83–146]</td><td align="left">F(3) = 16.78 p &lt; 0.001</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left">Performance IQd</td><td align="left">12</td><td align="left">106 (17.0) [59–157]</td><td align="left">104 (17.1) [67–148]</td><td align="left">109 (14.2) [62–147]</td><td align="left">109 (13.2) [79–145]</td><td align="left">F(3) = 3.1 p = 0.03</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left">Mean FD</td><td align="left">13</td><td align="left">0.11 (0.07) [0.02–0.39]</td><td align="left">0.13 (0.09) [0.02–0.39]</td><td align="left">0.09 (0.06) [0.02–0.39]</td><td align="left">0.09 (0.06) [0.02–0.38]</td><td align="left">H(3) = 29.6 p &lt; 0.001</td><td align="left">(ASD M = ASD F) &lt; (NT M = NT F)</td></tr><tr><td align="left" colspan="8">ADI-R</td></tr><tr><td align="left">Sociale</td><td align="left">11</td><td align="left">19.7 (5.2) [4–30]</td><td align="left">19.6 (5.5) [7–30]</td><td align="left">–</td><td align="left">–</td><td align="left">t(93) = 0.14 p = 0.89</td><td align="left"/></tr><tr><td align="left">Communicationf</td><td align="left">11</td><td align="left">15.6 (4.5) [2–25]</td><td align="left">15.2 (5.0) [4–24]</td><td align="left">–</td><td align="left">–</td><td align="left">t(92) = 0.61 p = 0.54</td><td align="left"/></tr><tr><td align="left">RRBf</td><td align="left">11</td><td align="left">6.0 (2.4) [0–13]</td><td align="left">5.8 (2.5) [0–12]</td><td align="left">–</td><td align="left">–</td><td align="left">t(96) = 0.51 p = 0.61</td><td align="left"/></tr><tr><td align="left" colspan="8">ADOS-2</td></tr><tr><td align="left">Social-Affectg</td><td align="left">11</td><td align="left">9.1 (3.7) [1–20]</td><td align="left">8.7 (3.2) [4–18]</td><td align="left">–</td><td align="left">–</td><td align="left">t(87) = 0.97 p = 0.33</td><td align="left"/></tr><tr><td align="left">RRBh</td><td align="left">11</td><td align="left">3.2 (1.8) [0–8]</td><td align="left">2.8 (1.5) [0–5]</td><td align="left">–</td><td align="left">–</td><td align="left">t(93) = 1.79 p = 0.08</td><td align="left"/></tr><tr><td align="left">CSS totali</td><td align="left">11</td><td align="left">6.9 (2.1) [1–10]</td><td align="left">6.8 (1.8) [2–10]</td><td align="left">–</td><td align="left">–</td><td align="left">t(93) = 0.11 p = 0.32</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">N</td><td align="left">N</td><td align="left"/><td align="left"/><td align="left">Statistics</td><td align="left">Post-hoc</td></tr><tr><td align="left">Comorbidity</td><td align="left">5</td><td align="left">99j</td><td align="left">25k</td><td align="left">–</td><td align="left">–</td><td align="left">χ2(1) = 0.2 p = 0.66</td><td align="left"/></tr><tr><td align="left">Psychoactive medication</td><td align="left">10</td><td align="left">112</td><td align="left">26</td><td align="left">–</td><td align="left">–</td><td align="left">χ2(1) &lt; 0.01 p = 0.99</td><td align="left"/></tr></tbody></table></div>ABIDE Autism Brain Imaging data exchange, ADI-R Autism Diagnostic Interview-Revised, ADOS-2 Autism Diagnostic Observation Schedule-2, ASD Autism Spectrum Disorder, CSS Calibrated Severity Score, F females, IQ intellectual quotient, M males, Mean FD mean framewise displacement [???]; NT neurotypical, RRB restricted repetitive behaviorsaABIDE I data collections: KKI, Leuven2, NYU, OHSU, Pitt, SDSU, Stanford, UCLA1, UM1, and Yale. ABIDE II data collections: ABIDEII-GU1, ABIDEII-KKI1, ABIDEII-KKI2, ABIDEII-NYU1, ABIDEII-OHSU1, ABIDEII-SDSU1, ABIDEII-UCD1 and ABIDEII-UCLA1. KKI and ABIDEII-KKI1, NYU and ABIDEII-NYU1, SDSU and ABIDEII-SDSU1, OHSU and ABIDEII-OHSU1 and UCLA1 and ABIDEII-UCLA1 were merged into one site across ABIDE I and ABIDE II collectionsbFIQ was available for 362 males with ASD (2 missing from UM1, ABIDEII-SDSU1), 81 females with ASD (1 missing from ABIDEII-GU1), 407 neurotypical males (NT M) [3 missing from ABIDEII-GU1 (N = 1), UM1 (N = 2)] and all 166 NT females (NT F)cVIQ was available for 315 males with ASD (47 missing; KKI (N = 14), ABIDEII-OHSU1 (N = 22), OHSU (N = 9), ABIDEII-SDSU1 (N = 1); ABIDEII-UCLA1 (N = 1), 70 females with ASD [12 missing, ABIDEII-GU1 (N = 1), KKI (N = 4), ABIDEII-OHSU1 (N = 7)], 351 NT M [59 missing; ABIDEII-GU1 (N = 1), KKI (N = 23), OHSU (N = 15), ABIDEII-OHSU1 (N = 20)], and 139 NT F [27 missing; KKI (N = 8), ABIDEII-OHSU1 (N = 19)]dPIQ was available for 306 males with ASD [56 missing; ABIDEII-GU1 (N = 9), KKI (N = 14), OHSU (N = 9), ABIDEII-OHSU1 (N = 22), ABIDEII-UCLA1 (N = 1), UM1, (N = 1)], 67 females with ASD [15 missing; ABIDEII-GU1 (N = 4), KKI (N = 4), ABIDEII-OHSU1 (N = 7)], 349 NT M [61 missing; ABIDEII-GU1 (N = 1), KKI (N = 23), OHSU (N = 15), ABIDEII-OHSU1 (N = 20), UM1, (N = 2)], 139 NT F [27 missing; KKI (N = 8), ABIDEII-OHSU1 (N = 19)]eADI-R Social scores were available for 317 males with ASD [45 missing; ABIDEII-GU1 (N = 1), Leuven2 (N = 10), NYU (N = 3), ABIDEII-NYU1 (N = 1), SDSU (N = 2), ABIDEII-UCD1 (N = 11), ABIDEII-UCLA1 (N = 14), UM1, (N = 2), Yale (N = 3)] and 68 females with ASD [14 missing; ABIDEII-GU1 (N = 1), ABIDEII-KKI1 (N = 2), Leuven2 (N = 3), NYU (N = 1), Pitt (N = 1), ABIDEII-UCD1 (N = 3), ABIDEII-UCLA1 (N = 1), Yale (N = 2)]fADI-R Communication and RRB scores were available for 318 males with ASD [45 missing; ABIDEII-GU1 (N = 1), Leuven2 (N = 10), NYU (N = 2), ABIDEII-NYU1 (N = 1), SDSU (N = 2), ABIDEII-UCD1 (N = 11), ABIDEII-UCLA1 (N = 14), UM1, (N = 2), Yale (N = 3)] and 68 females with ASD [14 missing; ABIDEII-GU1 (N = 1), ABIDEII-KKI1 (N = 2), Leuven2 (N = 3), NYU (N = 1), Pitt (N = 1), ABIDEII-UCD1 (N = 3), ABIDEII-UCLA1 (N = 1), Yale (N = 2)]gADOS-Gotham Social-Affect was available for 261 males with ASD [101 missing; ABIDEII-GU1 (N = 27), ABIDEII-KKI1 (N = 13), Leuven2 (N = 10), NYU (N = 7), OHSU (N = 11), Pitt (N = 8), SDSU (N = 8), Stanford (N = 6), ABIDEII-UCLA1 (N = 5), UM1 (N = 6), Yale (N = 1)] and 55 females with ASD [27 missing; ABIDEII-GU1 (N = 6), ABIDEII-KKI1 (N = 7), Leuven2 (N = 3), ABIDEII-OHSU1 (N = 1), Pitt (N = 4), Stanford (N = 1), ABIDEII-UCD1 (N = 1), UCLA1 (N = 1), UM1 (N = 3)]hADOS-Gotham RRB was available for 264 males with ASD [98 missing; ABIDEII-GU1 (N = 27), ABIDEII-KKI1 (N = 13), Leuven2 (N = 10), NYU (N = 7), OHSU (N = 11), Pitt (N = 8), SDSU (N = 8), Stanford (N = 3), ABIDEII-UCLA1 (N = 5), UM1 (N = 6), Yale (N = 1)] and 56 females with ASD [26 missing; ABIDEII-GU1 (N = 6), ABIDEII-KKI1 (N = 7), Leuven2 (N = 3), ABIDEII-OHSU1 (N = 1), Pitt (N = 4), ABIDEII-UCD1 (N = 1), UCLA1 (N = 1), UM1 (N = 3)]iADOS-Gotham calibrated severity scores [???] were available for 347 males with ASD (15 missing) and 77 females with ASD (5 missing)jAttention Deficit Hyperactivity Disorder (ADHD; N = 63); anxiety disorder (N = 22); Oppositional Defiant Disorder (ODD; N = 17); mood disorder (N = 11); Tourettes/Tics (N = 6); Obsessive–Compulsive Disorder (OCD; N = 6); enuresis (N = 8); encopresis (N = 4); developmental articulation disorder (N = 1); developmental dyslexia (N = 1); sensory integration disorder (N = 1)kADHD (N = 17); anxiety disorder (N = 7); ODD (N = 10); mood disorder (N = 2); OCD (N = 2); enuresis (N = 2); encopresis (N = 1). The three group means were compared with ANOVA tests (or Kruskal–Wallis test in the case of non-parametric mean FD) followed by post-hoc pairwise t test comparisons (or Mann–Whitney U tests in the case of non-parametric mean FD) when statistically significant (significance cut-off set at p &lt; 0.05)</transformed-table></extracted-table></extracted-tables-set>